Literature DB >> 12089373

Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.

Zemin Cao1, Fabrice Bonnet, Riccardo Candido, Stefan P Nesteroff, Wendy C Burns, Hiroshi Kawachi, Fujio Shimizu, Robert M Carey, Marc De Gasparo, Mark E Cooper.   

Abstract

The role of the angiotensin type 2 (AT(2)) receptor in the pathogenesis of progressive renal injury has not been previously elucidated. The renal expression of the AT(1) and AT(2) receptors in subtotally nephrectomized rats (STNx) and the effects of AT(2) receptor blockade on renal injury were explored. Reduced renal expression of the AT(1) but not the AT(2) receptor was observed in STNx by reverse transcription-PCR, by in vitro autoradiography, and by immunohistochemical staining. The STNx rats were randomly assigned to AT(1) receptor antagonist valsartan, AT(2) receptor antagonist PD123319, or the combination of both for 4 wk. Increased proteinuria in STNx rats was reduced by PD123319 but to a lesser degree when compared with valsartan. Reduced gene and protein expression of the slit diaphragm protein nephrin was prevented by either valsartan or PD123319. Expression of osteopontin, proliferating cell nuclear antigen, and monocyte/macrophage infiltration was increased in STNx rats and was reduced by both AT(1) and AT(2) receptor antagonists. These effects of AT(2) receptor antagonism were observed in the presence of increased BP in STNx rats. These findings suggest that blockade of the AT(2) receptor alone confers a degree of renal protection; in particular, it seems that the combination of the AT(1) and AT(2) receptor antagonists may confer additive renal effects than either receptor antagonist as monotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089373     DOI: 10.1097/01.asn.0000019409.17099.33

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  38 in total

Review 1.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

Review 2.  Antiproteinuric effect of RAS blockade: new mechanisms.

Authors:  Markus Lassila; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

3.  Clinical trials report. Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Authors:  Norman M Kaplan
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

4.  Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.

Authors:  Swayam Prakash Srivastava; Julie E Goodwin; Keizo Kanasaki; Daisuke Koya
Journal:  Br J Pharmacol       Date:  2020-06-22       Impact factor: 8.739

5.  Congenital nephrotic syndrome responsive to angiotensin-converting enzyme inhibition.

Authors:  Rajasree Sreedharan; Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2005-06-18       Impact factor: 3.714

Review 6.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

7.  A possible anti-inflammatory role of angiotensin II type 2 receptor in immune-mediated glomerulonephritis during type 1 receptor blockade.

Authors:  Hirokazu Okada; Tsutomu Inoue; Tomohiro Kikuta; Yusuke Watanabe; Yoshihiko Kanno; Shinichi Ban; Takeshi Sugaya; Masatsugu Horiuchi; Hiromichi Suzuki
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

Review 8.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

9.  Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.

Authors:  B J Davis; C I Johnston; L M Burrell; W C Burns; E Kubota; Z Cao; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2003-06-28       Impact factor: 10.122

10.  Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.

Authors:  A Koïtka; Z Cao; P Koh; A M D Watson; K C Sourris; L Loufrani; A Soro-Paavonen; T Walther; K J Woollard; K A M Jandeleit-Dahm; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2009-12-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.